 Nkarta Inc NASDAQ: NKTX has revealed the first human results from its two lead off-the-shelf NK cell therapies, with the high-dose regimens exhibiting multiple complete responses in blood cancer patients. For NKX101, three patients achieved a complete response CR among. 